Señales en vivo de LYRA | Maximiza tus Ganancias con Getagraph.com

COMPRAR 117974 min ago

@ $4.78

Emitido: 14 feb 2024 @ 15:33

Retorno: -89.39%

Señal anterior: feb 9 - 14:49

Señal anterior: Vender

Retorno: 2.36 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 14:48):

Stats
Volumen de hoy	100.33M
Volumen promedio	373 395
Capitalización de mercado	30.30M
EPS	$0 ( 2024-04-03 )
Próxima fecha de ganancias	( $-0.260 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.400
ATR14	$0.00300 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Waksal Harlan	Buy	275 000	Common Stock
2024-03-18	Palasis Maria	Buy	500 000	Stock Option
2024-01-30	Bishop John E	Buy	200 000	Stock Options
2024-01-30	Nieman Richard	Buy	200 000	Stock Options
2024-01-30	Cavalier Jason	Buy	200 000	Stock Options

INSIDER POWER
100.00
Last 92 transactions
Buy: 35 062 945 \| Sell: 0

Volumen Correlación

Largo: 0.27 (neutral)

Corto: -0.89 (strong negative)

Signal:(43.349) Neutral

Lyra Therapeutics Inc Correlación

10 Correlaciones Más Positivas
BCPC	0.85
NVNO	0.819
FICS	0.815
GRNQ	0.809
CD	0.802

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lyra Therapeutics Inc Correlación - Moneda/Commodity

0.23
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.15
( neutral )

Lyra Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$1.56M
Beneficio Bruto:	$1.28M (82.16 %)
EPS:	$-1.260

FY	2023
Ingresos:	$1.56M
Beneficio Bruto:	$1.28M (82.16 %)
EPS:	$-1.260

FY	2022
Ingresos:	$1.36M
Beneficio Bruto:	$296 000 (21.72 %)
EPS:	$-1.830

FY	2021
Ingresos:	$285 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.35

Financial Reports:

No articles found.

Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Actualizaciones en tiempo real para Lyra Therapeutics Inc [LYRA]

Upcoming Earnings Alert